DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Clinical trials for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for hard-to-treat cancers with missing MTAP gene
Disease control Not yet recruitingThis early-phase study tests a new drug called CS08399 in people with advanced solid tumors or lymphoma that have a missing MTAP gene. The main goals are to find a safe dose and see how the drug works in the body. About 186 adults will take part, and the study will also check if …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated May 26, 2026 10:36 UTC
-
Experimental Dual-Targeting cell therapy takes on tough lymphomas
Disease control Not yet recruitingThis early-phase study tests a new type of immune cell therapy (bispecific AbTCR-T cells) in 3 adults with relapsed or refractory B-cell lymphoma. The cells are designed to recognize two targets (CD19 and CD22) on cancer cells. The main goal is to check safety and side effects, w…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: EARLY_PHASE1 • Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated May 26, 2026 10:32 UTC
-
New hope for elderly lymphoma patients: drug combo targets tough cancer
Disease control Not yet recruitingThis study tests whether adding two targeted drugs (mosunetuzumab and polatuzumab vedotin) to standard chemotherapy can help older adults (70+) with a newly diagnosed, aggressive type of lymphoma called diffuse large B-cell lymphoma. About 31 participants will receive this combin…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated May 26, 2026 10:28 UTC
-
New hope for lymphoma patients: experimental drug added to standard chemo
Disease control Not yet recruitingThis study tests whether adding the experimental drug lisatoclax to standard chemotherapy (R-CHOP or Pola-R-CHP) can improve outcomes for people with untreated diffuse large B-cell lymphoma (DLBCL). About 122 adults aged 18-70 will take part. The goal is to see if the combination…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 26, 2026 10:23 UTC
-
New hope for lymphoma patients: drug combo aims to boost chemo
Disease control Not yet recruitingThis study tests whether adding the drug epcoritamab to standard chemotherapy (R-CHOP) is safe and effective for people newly diagnosed with aggressive B-cell non-Hodgkin lymphoma. About 20 adults will receive the combination treatment. The main goal is to check for side effects …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Mwanasha Merrill, MD • Aim: Disease control
Last updated May 26, 2026 10:23 UTC
-
Hope for Hard-to-Treat lymphoma: arthritis drug joins chemo in new trial
Disease control Not yet recruitingThis study tests whether adding the arthritis drug celecoxib to standard chemotherapy (R-CHOP) works better than chemo alone for people with a specific, aggressive type of lymphoma (CD5-positive DLBCL). About 60 adults with newly diagnosed advanced disease will be randomly assign…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
Can radiation and a common antibiotic boost CAR-T therapy for lymphoma?
Disease control Not yet recruitingThis early-stage trial tests whether giving radiation therapy and the antibiotic vancomycin before CAR-T cell treatment is safe and doable for people with large B-cell lymphoma. The study will enroll 14 adults whose lymphoma has come back or not responded to other treatments. The…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Colombia launches first CAR-T trial for relapsed blood cancers
Disease control Not yet recruitingThis study aims to bring a personalized cell therapy called CAR-T to Colombia for people with certain blood cancers that have come back or not responded to treatment. The therapy involves modifying a patient's own immune cells to attack cancer. The trial will check if it is safe …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: NA • Sponsor: GUSTAVO SALGUERO • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New study to track brain health in lymphoma patients after CAR-T therapy
Knowledge-focused Not yet recruitingThis study follows 100 adults with certain types of lymphoma who are receiving CAR-T cell therapy. Researchers will test their thinking, memory, and quality of life before treatment and again at 6, 12, and 24 months after. The goal is to understand how the therapy affects brain f…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated May 26, 2026 10:34 UTC
-
What's next after pola fails? new study tracks lymphoma patients' next moves
Knowledge-focused Not yet recruitingThis study follows 200 adults with diffuse large B-cell lymphoma whose cancer got worse after treatment with polatuzumab vedotin. Researchers will track what treatments doctors try next and how well they work. The goal is to gather real-world data to help guide better treatment d…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Peking Union Medical College Hospital • Aim: Knowledge-focused
Last updated May 26, 2026 10:27 UTC